Relamorelin for Diabetic Gastroparesis: A Ghrelin Agonist Prokinetic

The clinical problem

Diabetic gastroparesis is delayed emptying of the stomach that occurs, over years, in some people with diabetes when nerve damage impairs the stomach's ability to contract and push food onward. Symptoms include nausea, vomiting, early fullness, bloating, and unpredictable blood-sugar swings because food reaches the intestine erratically. It can be difficult to manage: dietary measures help some patients, and the available prokinetic drugs are limited by side effects or restricted approvals. There is a clear need for better options. This use case is educational; gastroparesis is managed by clinicians.

The rationale for a ghrelin agonist

The stomach hormone ghrelin does more than stimulate appetite — acting on the GHSR-1a receptor it also promotes gastric motility, including the fasting contractions of the migrating motor complex. This makes the ghrelin receptor an attractive target for a prokinetic: a drug that speeds up gut movement.

Relamorelin is an injectable ghrelin/GHSR receptor agonist developed for exactly this purpose. Rather than aiming at appetite or wasting, it is designed to accelerate gastric emptying and thereby relieve the symptoms that come from food sitting too long in the stomach. It is being studied specifically in gastroparesis, with a focus on patients who also have type 2 diabetes.

What the evidence showed

Relamorelin has been evaluated in mid-stage (phase 2) clinical trials in diabetic gastroparesis. In this program it accelerated gastric emptying and showed positive effects on core symptoms, including vomiting, consistent with its prokinetic mechanism. These results were encouraging enough to support continued development.

However, relamorelin is not approved anywhere for gastroparesis. It remains investigational (research-only), and later-stage confirmation and regulatory review would be required before it could become an established treatment. As with any drug that affects gut hormones and motility, longer and larger studies are needed to confirm both benefit and safety over time. We deliberately avoid citing precise trial percentages here; the qualitative signal — faster emptying and fewer symptoms versus placebo — is what the phase 2 data suggested.

Where it fits

If it were ultimately approved, relamorelin would sit alongside existing prokinetics as an option aimed at the underlying motility problem. It is distinct from other ghrelin-receptor drugs by intent: anamorelin targets cancer cachexia and appetite, while relamorelin targets gastric emptying. Both exploit the same receptor first characterized for ghrelin, a reminder that a single receptor can be steered toward very different clinical goals.

Other hormonal prokinetic strategies exist too. Agonists of the motilin receptor — the hormone that drives the gut's fasting housekeeper wave — have long been pursued for the same problem, illustrating how gut-motility disorders draw on the whole family of motility hormones.

The bottom line

Relamorelin is a promising, mechanistically logical candidate for diabetic gastroparesis: it turns the ghrelin receptor's natural prokinetic action into a targeted therapy. Its phase 2 results were positive, but it is not yet approved and remains investigational. Patients with gastroparesis should rely on currently available, clinician-directed management and regard relamorelin as a drug still under study.

This use case is educational and not medical advice. Relamorelin is investigational and not approved; gastroparesis should be managed by a qualified clinician.